Abstract: Described herein is a solid tablet that is directly-compressed of powder, including meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.

Abstract: A method for treating pain, inflammation, fever and respiratory complaints in mammals comprising administering by needleless injection to a mammal in need of such treatment an aqueous cyclodextrin-free solution of meloxicam containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base.

Abstract: Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The formulation according to the invention has a shelf-life of up to 24 months or more.

Abstract: An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients.

Abstract: Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The solution is for treating a mammal suffering from one or more of pain, inflammation, fever, acute mastitis, diarrhea, lameness, locomotor deficiency, or respiratory illness.

Abstract: A solid tablet formed through direct compression of powder, the powder comprising meloxicam as an active ingredient and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the meloxicam.

Abstract: A solid formulation includes pimobendan or a pharmaceutically acceptable salt thereof, which is homogenously dispersed with a polyvalent acid and a flavor suitable to animals.

Abstract: Described herein is a solid tablet that is directly-compressed of powder, including meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.

Abstract: A method of treating animals includes administering water soluble granules to an animal, where the water soluble granules include meloxicam, salt forming agent operable to form a meloxicam salt, a binder, and a carrier.

Abstract: The invention relates to a solid tablet that is directly-compressed of powder, comprising meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.

Abstract: Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The solution is for treating a mammal suffering from one or more of pain, inflammation, fever, acute mastitis, diarrhea, lameness, locomotor deficiency, or respiratory illness.

Abstract: A plastic container containing a pharmaceutical composition comprising benzoic acid or a derivative or a pharmaceutically acceptable salt thereof and a COX-inhibitor of the oxicam-type or a pharmaceutical acceptable salt thereof, wherein the container material selected from one or more members of the group consisting of a homopolymer of polypropylene (PP), a copolymer of polypropylene (PP), a homopolymer of polyethylene terephthalate (PET) and a copolymer of polyethylene terephthalate (PET), and optionally one or more non-polymeric components.

Abstract: A plastic container containing a pharmaceutical composition comprising benzoic acid or a derivative or a pharmaceutically acceptable salt thereof and a COX-inhibitor of the oxicam-type or a pharmaceutical acceptable salt thereof, wherein the container material selected from one or more members of the group consisting of a homopolymer of polypropylene (PP), a copolymer of polypropylene (PP), a homopolymer of polyethylene terephthalate (PET) and a copolymer of polyethylene terephthalate (PET), and optionally one or more non-polymeric components.

Abstract: Water soluble meloxicam granules include meloxicam, a salt forming agent which forms the meglumine, sodium, potassium, or ammonium salt of meloxicam, a binder, a sugar or sweetener, and a carrier, and a flavoring agent.

Abstract: An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients.

Abstract: An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients.

Abstract: A solid formulation includes pimobendan or a pharmaceutically acceptable salt thereof, which is homogenously dispersed with a polyvalent acid and a flavor suitable to animals.

Abstract: A method of treating animals includes administering water soluble granules to an animal, where the water soluble granules include meloxicam, salt forming agent operable to form a meloxicam salt, a binder, and a carrier.

Abstract: A packaging assembly or kit includes packaging material containing a solid formulation including pimobendan dispersed in a polyvalent acid. The kit may also include a package leaflet or user instruction including the information concerning use of the solid formulation, for example, via the oral route for the prevention and/or treatment of congestive heart failure in a mammal in need of such prevention or treatment, preferably in a dog, cat or rodent.

Abstract: The invention relates to novel solid formulations comprising as pharmaceutically active compound pimobendan and to processes for producing such solid formulations. The invention furthermore relates to a method for manufacturing a medicament for the prevention and/or treatment of congestive heart failure, wherein the solid formulations according to the invention are used.